Given contradictions or evidence gaps regarding modulation of ACPA levels, the present study aims to analyze which variables can influence the levels of anti-CCP ACPA in patients with EA, taking advantage of our PEARL (Princesa Early Arthritis Longitudinal) study, in which most patients have not received DMARD treatment at recruitment. This evidence concerns the gene PRTN3 and Arthritis.